BIOMARKER PADA LUPUS NEFRITIS

Bilah Samping Artikel

PDF (English)
Diterbitkan: Nov 20, 2023
DOI: https://doi.org/10.37715/pmj.v4i2.4559

Isi Artikel Utama

Gisela Tania Irwanto
Dokter Umum Rumah Sakit Karanggede Sisma Medika Boyolali Jawa Tengah Indonesia
Yuswanto Setyawan
Departemen Ilmu Penyakit Dalam Universitas Ciputra Surabaya Jawa Timur Indonesia

Abstrak

Lupus nefritis (LN) terus menjadi penyebab utama tingginya tingkat morbiditas dan mortalitas pada pasien lupus eritematosus sistemik (SLE). Biopsi ginjal masih menjadi sebagai baku emas untuk mendiagnosis LN. Beberapa biomarker telah diidentifikasi dan dievaluasi yang meningkatkan perbaikan dalam manajemen pasien dengan LN. Tinjauan pustaka ini merangkum literatur terkini yang relevan dengan biomarker untuk diagnosis, pemantauan, dan prognosis LN. Biomarker ini dikategorikan berdasarkan sumber sampelnya, yaitu serum dan urin. Kedua sumber sampel ini menunjukkan variasi data dari biomarker yang signifikan berkaitan dengan aktivitas penyakit dan parameter histologis LN. Molekul-molekul potensial biomarker tersebut merupakan molekul-molekul seperti, antibodi, sitokin, kemokin, dan molekul adhesi. Tinjauan pustaka ini memberikan gambaran umum dan harapannya dapat menjadi acuan untuk penelitian lebih lanjut, khususnya dalam konteks pemahaman biomarker LN yang lebih mendalam di Indonesia.


Kata kunci: lupus eritematosus sistemik (SLE), lupus nefritis (LN), biomarker, serum, urin

Rincian Artikel

Cara Mengutip
Irwanto, G. T., & Setyawan, Y. (2023). BIOMARKER PADA LUPUS NEFRITIS. Prominentia Medical Journal, 4(2), 56–72. https://doi.org/10.37715/pmj.v4i2.4559
Terbitan
Vol 4 No 2 (2023): Prominentia Medical Journal
Bagian
Articles
Creative Commons License

Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.

Referensi

Bruschi, M. et al. (2021) ‘Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis’, Rheumatology, 60(7), pp. 3176–3188. Available at: https://doi.org/10.1093/rheumatology/keaa767.

Califf, R.M. (2018) ‘Biomarker definitions and their applications’, Experimental Biology and Medicine, 243(3), pp. 213–221. Available at: https://doi.org/10.1177/1535370217750088.

Chalmers, S.A. et al. (2022) ‘The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses’, Journal of Clinical Investigation, 132(1), pp. 1-17. Available at: https://doi.org/10.1172/JCI147334.

Choe, J.-Y. and Kim, S.-K. (2016) ‘Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus’, Inflammation Research, 65(6), pp. 479–488. Available at: https://doi.org/10.1007/s00011-016-0930-5.

Choe, J.-Y., Park, S.-H. and Kim, S.-K. (2014) ‘Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus’, Lupus, 23(14), pp. 1486–1493. Available at: https://doi.org/10.1177/0961203314547797.

Ding, H. et al. (2016) ‘Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis’, Clinical and Experimental Immunology, 184(1), pp. 11–18. Available at: https://doi.org/10.1111/cei.12743.

Ding, H. et al. (2020) ‘Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology’, Arthritis Research & Therapy, 22(1), pp. 1-9. Available at: https://doi.org/10.1186/s13075-020-02209-9.

Gómez-Puerta, J.A. et al. (2018) ‘Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients’, Lupus, 27(4), pp. 637–646. Available at: https://doi.org/10.1177/0961203317738226.

Hafez, E.A. et al. (2021) ‘Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus’, Lupus, 30(3), pp. 378–384. Available at: https://doi.org/10.1177/0961203320979042.

Hardt, U. et al. (2018) ‘Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis’, Arthritis Research & Therapy, 20(1), pp. 1-12. Available at: https://doi.org/10.1186/s13075-018-1530-2.

Kato, Y. et al. (2020) ‘Anti-enolase１antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells’, Immunology Letters, 218, pp. 22–29. Available at: https://doi.org/10.1016/j.imlet.2019.12.005.

Kementerian Kesehatan Republik Indonesia (2017) Situasi Lupus di Indonesia. Jakarta.

Lou, H. et al. (2020) ‘Autoantibody-dependent amplification of inflammation in SLE’, Cell Death & Disease, 11(9), pp. 1-15. Available at: https://doi.org/10.1038/s41419-020-02928-6.

Martin, M. et al. (2020) ‘Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients’, Frontiers in Immunology, 11, pp. 1-11. Available at: https://doi.org/10.3389/fimmu.2020.582737.

Tanzilia, M.F., Tambunan, B.A. and Dewi, D.N.S.S. (2021) ‘Tinjauan Pustaka: Patogenesis dan Diagnosis Sistemik Lupus Eritematosus’, Syifa’ MEDIKA: Jurnal Kedokteran dan Kesehatan, 11(2), pp. 139–164.

Mok, C.C. (2010) ‘Biomarkers for Lupus Nephritis: A Critical Appraisal’, Journal of Biomedicine and Biotechnology, 2010, pp. 1–11. Available at: https://doi.org/10.1155/2010/638413.

Mok, C.C. et al. (2016) ‘Axl, Ferritin, Insulin‐Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus’, Arthritis Care & Research, 68(9), pp. 1303–1309. Available at: https://doi.org/10.1002/acr.22835.

Mok, C.C. et al. (2018) ‘Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis’, Arthritis Research & Therapy, 20(1), pp. 1-10. Available at: https://doi.org/10.1186/s13075-017-1498-3.

Okba, A.M. et al. (2019) ‘Hyperuricemia as an independent predictor and prognostic factor in the development of lupus nephritis’, International Journal of Clinical Rheumatology, 14(3), pp. 91–98.

Palazzo, L. et al. (2022) ‘Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature’, Journal of Clinical Medicine, 11(19), pp. 1-30. Available at: https://doi.org/10.3390/jcm11195759.

Pang, Y. et al. (2016) ‘Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis’, Kidney International, 90(6), pp. 1357–1367. Available at: https://doi.org/10.1016/j.kint.2016.08.010.

Phatak, S. et al. (2017) ‘Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis’, Clinical and Experimental Immunology, 187(3), pp. 376–382. Available at: https://doi.org/10.1111/cei.12894.

Ren, Y. et al. (2018) ‘Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study’, International Immunopharmacology, 60, pp. 189–193. Available at: https://doi.org/10.1016/j.intimp.2018.04.048.

Reyes-Martínez, F. et al. (2018) ‘Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: An exploratory study’, Nefrología, 38(2), pp. 152–160. Available at: https://doi.org/10.1016/j.nefro.2017.04.005.

Salem, M.N. et al. (2018) ‘Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis’, Zeitschrift für Rheumatologie, 77(1), pp. 71–77. Available at: https://doi.org/10.1007/s00393-016-0184-1.

Setiati, S., Alwi, I. and Sudoyo, A. (2014) Buku Ajar Ilmu Penyakit Dalam. 1st edn. Jakarta: InternaPublishing.

Singh, S. et al. (2012) ‘Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis’, Arthritis Research & Therapy, 14(4), pp. 1-11. Available at: https://doi.org/10.1186/ar3912.

Soliman, S. et al. (2017) ‘Urine angiostatin and VCAM ‐1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis’, International Journal of Rheumatic Diseases, 20(11), pp. 1714–1727. Available at: https://doi.org/10.1111/1756-185X.13197.

Soliman, S. and Mohan, C. (2017) ‘Lupus nephritis biomarkers’, Clinical Immunology, 185, pp. 10–20. Available at: https://doi.org/10.1016/j.clim.2016.08.001.

Susianti, H. et al. (2014) ‘Analysis of urinary TGF- β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis’, Pathophysiology, pp. 4-7. Available at: http://dx.doi.org/10.1016/j.pathophys.2014.12.003.

Tan, Y. et al. (2013) ‘Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis’, BMC Nephrology, 14(1), pp. 1-10. Available at: https://doi.org/10.1186/1471-2369-14-63.

Tang, C. et al. (2022) ‘Discovery of Novel Circulating Immune Complexes in Lupus Nephritis Using Immunoproteomics’, Frontiers in Immunology, 13, pp. 1-12. Available at: https://doi.org/10.3389/fimmu.2022.850015.

Tjan, B., Kambayana, G. and Kurniari, P.K. (2022) ‘Gambaran profil systemic lupus erythematosus (SLE) dan lupus nefritis di Rumah Sakit Umum Pusat Sanglah’, Jurnal Penyakit Dalam Udayana, 6(2), pp. 31–35. Available at: https://doi.org/10.36216/jpd.v6i2.187.

Wang, X.-Y., Wang, B. and Wen, Y.-M. (2019) ‘From therapeutic antibodies to immune complex vaccines’, npj Vaccines, 4(1), pp.1-8. Available at: https://doi.org/10.1038/s41541-018-0095-z.

Wu, T. et al. (2016) ‘Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study’, Journal of Proteome Research, 15(7), pp. 2102–2114. Available at: https://doi.org/10.1021/acs.jproteome.5b00905.

Yu, F. et al. (2017) ‘Redefining lupus nephritis: clinical implications of pathophysiologic subtypes’, Nature Reviews Nephrology, 13(8), pp. 483–495. Available at: https://doi.org/10.1038/nrneph.2017.85.